Calypso Biotech is a biopharmaceutical company specializing in the development of therapeutic antibodies against severe (auto)immune diseases
Calypso Biotech is a biopharmaceutical company specializing in the development of therapeutic antibodies against severe (auto)immune diseases. Its lead program, CALY-002, targets interleukin-15 (IL-15) for the treatment of Eosinophilic Esophagitis (EoE), an immune pathology with significant unmet medical needs.